Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)

Rosa Ahn; Vinay Prasad

doi:10.1007/s10557-018-6834-6

Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)

Rosa Ahn, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below.

Original language	English (US)
Pages (from-to)	637
Number of pages	1
Journal	Cardiovascular Drugs and Therapy
Volume	32
Issue number	6
DOIs	https://doi.org/10.1007/s10557-018-6834-6
State	Published - Dec 1 2018

ASJC Scopus subject areas

Pharmacology
Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1007/s10557-018-6834-6

Fingerprint

Dive into the research topics of 'Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)'. Together they form a unique fingerprint.

Cite this

Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x). / Ahn, Rosa; Prasad, Vinay.
In: Cardiovascular Drugs and Therapy, Vol. 32, No. 6, 01.12.2018, p. 637.

Research output: Contribution to journal › Comment/debate › peer-review

@article{a8045f5c5d6b4bd1980ae56a9fc9adff,

title = "Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)",

abstract = "The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; {"}320 mg twice a day{"} should read {"}160mg twice a day{"}. The corrected paragraph is shown below.",

author = "Rosa Ahn and Vinay Prasad",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = dec,

day = "1",

doi = "10.1007/s10557-018-6834-6",

language = "English (US)",

volume = "32",

pages = "637",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "6",

}

TY - JOUR

T1 - Correction to

T2 - Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)

AU - Ahn, Rosa

AU - Prasad, Vinay

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below.

AB - The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below.

UR - http://www.scopus.com/inward/record.url?scp=85054327093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054327093&partnerID=8YFLogxK

U2 - 10.1007/s10557-018-6834-6

DO - 10.1007/s10557-018-6834-6

M3 - Comment/debate

C2 - 30276760

AN - SCOPUS:85054327093

SN - 0920-3206

VL - 32

SP - 637

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

IS - 6

ER -

Correction to: Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)? (Cardiovascular Drugs and Therapy, (2018), 32, 6, (633-635), 10.1007/s10557-018-6830-x)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this